Antibiotics in phase II and III clinical trials

Handbook of Experimental Pharmacology

Volumn 211, Issue , 2012, Pages 167-183

  Coates, Anthony R M ^a   Halls, Gerry ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b Medical Marketing Services   (United Kingdom)

Author keywords

Antibiotics; classes; clinical trials; combinations; Gram negatives; Gram positives; Phase II; Phase III; pipeline; regulation; resistance

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM; AZTREONAM; BC 3781; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CXA 201; DALBAVANCIN; DELAFLOXACIN; FINAFLOXACIN; GSK 1322322; GSK 2251052; ICLAPRIM; IMIPENEM; LINEZOLID; MK 7655; MODITHROMYCIN; ORITAVANCIN; PEPTIDE DEFORMYLASE INHIBITOR; PLAZOMICIN; PLEUROMUTILIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADEZOLID; SOLITHROMYCIN; TAZOBACTAM; TD 1792; TEDIZOLID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL WALL; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; DRUG URINE LEVEL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HELICOBACTER INFECTION; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; DRUG COMBINATION; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; REVIEW;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84869886623     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-28951-4_11     Document Type: Article

References (67)

1. Abandeh FI, Drew ME, Sopirala MM (2012) Carbapenem-hydrolyzing gram-negative bacteria: current options for treatment and review of drugs in development. Recent Pat Antiinfect Drug Discov 7(1):19-27
2. Becker D, Selbach M, Rollenhagen C, Ballmaier M, Meyer TF, Mann M, Bumann D (2006) Robust salmonella metabolism limits possibilities for new antimicrobials. Nature 16:303-307
3. Bell JM, Turnidge JD, Inoue M, Kohno S, Hirakata Y, Ono Y, Jones RN (2005) Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. J Antimicrob Chemother 55(2):276-278 (Pubitemid 40331161)
4. Belley A (2010) Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother 54:5369-5371
5. Boucher HW, Talbot GH et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1-12
6. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC (2011) Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther 9(9):775-85
7. Busse KH, Oltrogge KM, Oxencis CJ, Peppard WJ (2010) Dalbavancin: a review of its use in the treatment of gram-positive infections. Clin Med Insights Ther 2:7-13
8. Butler MS, Buss AD (2006) Natural products - the future scaffolds for novel antibiotics? Biochem Pharmacol 71(7):919-29
9. Butler MS, Cooper MA (2011) Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo) 64(6):413-25
10. Cantón R, Morosini MI (2011) Emergence and spread of antibiotic resistance following exposure to antibiotics. FEMS Microbiol Rev 35(5):977-91
11. Cass RT, Brooks CD, Havrilla NA, Tack KJ, Borin MT, Young D, Bruss JB (2011) Pharmacoki-netics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother 55(12):5874-80
12. Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, Margolis PS, Wu C, Ni ZJ, Trias J, White RJ, Yuan Z (2000) Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39(6):1256-62 (Pubitemid 30090692)
13. Chan M (2011) Combat drug resistance: no action today means no cure tomorrow. Statement by WHO Director-General, Dr Margaret Chan. World Health Day, 6 April 2011. http://www.who.int/mediacentre/news/statements/2011/whd-20110407/ en/index.html. Accessed 2nd February 2012
14. Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, Romesberg FE (2005) Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol 3(6):176
15. CMR International Institute for Regulatory Science in April 2003 in Nutfield, Surrey, UK
16. Coates AR, Hu Y (2007) Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol 152(8):1147-54 (Pubitemid 350242433)
17. Coates ARM, Halls G, Hu Y (2011) Novel classes of antibiotics or more of the same? Brit J Pharmacol 163:184-194
18. Covington P, Davenport JM, Andrae D, O'Riordan W, Liverman L, McIntyre G, Almenoff J (2011) Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob Agents Chemother 55(12):5790-7
19. Crofton J (1958) Sputum conversion and the metabolism of isoniazid. Am Rev Tuberc 77:869-871
20. D'Agata EM, Dupont-Rouzeyrol M, Magal P, Olivier D, Ruan S (2008) The impact of different antibiotic regimens on the emergence of antimicrobial- resistant bacteria. PLoS One 3(12):4036
21. D'Costa VM, King CE, Kalan L, Morar M, Sung WW, Schwarz C, Froese D, Zazula G, Calmels F, Debruyne R, Golding GB, Poinar HN, Wright GD (2011) Antibiotic resistance is ancient. Nature 477(7365):457-61
22. Dalhoff A, Stubbings W, Schubert S (2011) Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine. Antimicrob Agents Chemother 55(4):1814-8
23. Farrell DJ, Sader HS, Castanheira M, Biedenbach DJ, Rhomberg PR, Jones RN (2010) Antimicrobial characterization of CEM-101 activity against respiratory tract pathogens including multidrug-resistant pneumococcal serogroup 19A isolates. Int J Antimicrob Agent 35:537-543
24. Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN (2011) JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother 55(7):3631-4
25. Fox W, Sutherland I, Daniels M (1954) A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis. Q J Med 23:347-366
26. Fox W, Ellard GA, Mitchison DA (1999) Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3:S231-S279 (Pubitemid 29481843)
27. Freire-Moran L, Aronsson B, Manz C, Gyssens IC, So AD, Monnet DL, Cars O (2011) ECDC-EMA Working Group. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-time to react is now. Drug Resist Updat 14(2):118-24
28. Furuie H, Saisho Y, Yoshikawa T, Shimada J (2010) Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. Antimicrob Agents Chemother 54(2):866-70, Epub 2009 Nov 23
29. Ge Y, Whitehouse MJ, Friedland I, Talbot GH (2010) Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single-and multiple-dose intravenous infusions. Antimicrob Agents Chemother 54(8):3427-31
30. Haas DW (2000) Mycobacterial diseases, Chapter 240. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases, vol 2, 5th edn. Churchill Livingstone, Philadelphia, London, pp 2576-2607
31. Hair PI, Keam SJ (2007) Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs 67(10):1483-512 (Pubitemid 47028521)
32. http://www.farm.ucl.ac.be/Full-texts-FARM/Domenech-2009-1.pdf. "Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization" 2009
33. Johnson KW, Lofland D, Moser HE (2005) PDF inhibitors: an emerging class of antibacterial drugs. Curr Drug Target Infect Disord 5:39-52, 1568-0053/05 # 2005 Bentham Science Publishers Ltd (Pubitemid 40467699)
34. Hurdle JG, O'Neill AJ, Chopra I, Lee RE (2011) Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 9(1):62-75
35. Kohno S, Yamaguchi K, Tanigawara Y, Watanabe A, Aoki A, Niki Y, Fujita J (2007) Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., abstr. L-485
36. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtag S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological and epidemiological study. Lancet Infect Dis 10:597-602
37. Leuthner KD, Vidaillac C, Cheung CM, Rybak MJ (2010) In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylo-coccus isolates. Antimicrob Agents Chemother 54(9):3799-803, Epub 2010 Jun 28
38. Livermore DM, Mushtaq S, Ge Y (2010) Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 65(9):1972-4
39. Livermore DM, Warner MSM, Zhang J-C, Maharjan S, Doumith M, Woodford N (2011a) Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66(1):48-53
40. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N (2011b) Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 55(1):390-4
41. Locke JB, Finn J, Hilgers M, Morales G, Rahawi S, Picazo JJ, Im W, Shaw KJ, Stein JL (2010) Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococ-cus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Agents Chemother 54(12):5337-43
42. Mangion IK, Ruck RT, Rivera N, Huffman MA, Shevlin M (2011) A concise synthesis of a β-lactamase inhibitor. Org Lett 13(20):5480-3, http://antibiotics-theperfectstorm.blogspot.com/2010/09/superbug-ndm-1.html
43. Medical Research Council (1948) Streptomycin treatment of pulmonary tuberculosis. Br Med J 2:769-782
44. Medical Research Council (1950) Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid. Br Med J 2:1073-1085
45. Meyer AL (2005) Prospects and challenges of developing new agents for tough Gram-negatives. Curr Opin Pharmacol 5(5):490-4 (Pubitemid 41258565)
46. Mitchison DA (1954) Problems of drug resistance. Br Med Bull 69:640-641
47. Mitchison DA (1998) How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2:10-15 (Pubitemid 28108937)
48. Morgan A, Cofer C, Stevens DL (2009) Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections. Future Microbiol 4(2):131-44
49. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM (2010) Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobac-teriaceae. J Antimicrob Chemother 65(7):1428-32
50. No authors. (2009) Deal watch: Novartis acquires marketing rights for novel broad-spectrum antibiotic. Nat Rev Drug Discov 2009 (12):922
51. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6(1):29-40 (Pubitemid 46020284)
52. Peirano G, Pitout JD (2010) Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 35(4):316-21
53. Peppard WJ, Schuenke CD (2008) Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs 9(2):210-25 (Pubitemid 351206380)
54. Piel J (2011) Approaches to capturing and designing biologically active small molecules produced by uncultured microbes. Annu Rev Microbiol 65:431-53
55. Potron A, Poirel L, Nordmann P (2011) Plasmid-mediated transfer of the bla(NDM-1) gene in Gram-negative rods. FEMS Microbiol Lett 324(2):111-6
56. Rolan P, Sun H, MacLeod C, Bracken K, Evans TG (2011) Pharmacokinetics and unexpected safety issues of LBM415, a novel oral peptide deformylase inhibitor. Clin Pharmacol Ther 90 (2):256-262
57. Rubino C, Bhavnani S, Burak E, Ambrose P (2010) Pharmacokinetic- pharmacodynamic (PK-PD) target attainment (TA) analyses supporting delafloxacin (DFX) Phase 3 dose regimen decisions. ICAAC. http://www.drugs.com/clinical- trials/rib-x-pharmaceuticals-presents-data-supporting-delafloxacin-potential- best-class-fluoroquinolone-10109.html
58. Sato T, Tateda K, Kimura S, Iwata M, Ishii Y, Yamaguchi K (2011) In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci. Antimicrob Agents Chemother 55(4):1588-93, Epub 2011 Jan 10
59. Scheifele DW, Marty K, LaJeunesse C, Fan SY, Bjornson G, Langley JM, Halperin SA (2011) Strategies for successful rapid trials of influenza vaccine. Clin Trials 8(6):699-704
60. Scheinfeld N (2007) A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. J Drugs Dermatol 6(4):97-103
61. Shoemaker NB, Vlamakis H, Hayes K, Salyers AA (2001) Evidence for extensive resistance gene transfer among Bacteroides spp. and among Bacteroides and other genera in the human colon. Appl Environ Microbiol 67(2):561-8 (Pubitemid 32121342)
62. Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, Miossec C, Black MT (2009) In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 64(2):326-9
63. Stryjewski ME, Barriere SL, Kitt MM, Corey GR (2007) TD-1792 vs vancomycin (VAN) for treatment of complicated gram-positive skin and skin structure infections (cSSSIs), poster L-1147a. Abstract 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC
64. Sutcliffe JA (2011) Antibiotics in development targeting protein synthesis. Ann N Y Acad Sci 1241(1):122-52
65. Targanta Revives Oritavancin: Next Weapon Against cSSSI? BioWorld Today, November 26, 2007
66. Traugott KA, Echevarria K, Maxwell P, Green K, Lewis JS 2nd (2011) Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy 31(6):598-608
67. Wagenlehner FM, Wagenlehner CM, Blenk B, Blenk H, Schubert S, Dalhoff A, Naber KG (2011) Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose. Chemotherapy 57(2):97-107